Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1% – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares shot up 1% during trading on Tuesday . The company traded as high as $7.25 and last traded at $7.06. 7,639,385 shares were traded during trading, an increase of 12% from the average session volume of 6,791,037 shares. The stock had previously closed at $6.99.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Trading Up 3.6 %

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a 50 day simple moving average of $6.76 and a two-hundred day simple moving average of $7.16. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.43) earnings per share. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total transaction of $71,200.34. Following the completion of the transaction, the director now owns 7,098,428 shares in the company, valued at $44,152,222.16. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 107,788 shares of company stock worth $724,691 over the last quarter. 15.75% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently modified their holdings of the company. ARK Investment Management LLC increased its position in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after acquiring an additional 4,626,268 shares during the period. State Street Corp grew its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Lingotto Investment Management LLP increased its holdings in shares of Recursion Pharmaceuticals by 69.0% during the second quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the period. Ghisallo Capital Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at about $8,250,000. Finally, Perceptive Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter worth about $5,769,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.